Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28387150 | 0.98 | GBA1 (0.39) | GBA1ALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL8150738 | 0.93 | GBA1 (0.41) | GBA1ALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL1148956 | 0.91 | GBA1 (0.38) | GBA1ALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL10718132 | 0.83 | GBA1 (0.43) | GBA1ALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL6603710 | 0.83 | GBA1 (0.43) | GBA1ALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL15577392 | 0.80 | — | — | |
| SCHEMBL16710784 | 0.78 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL8427828 | 0.77 | GBA1 (0.36) | GBA1ALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL10774578 | 0.77 | CYP1A2 (0.43) | GBA1ALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL10774246 | 0.77 | CYP1A2 (0.43) | GBA1ALDH1A1LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180280367-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-10010538-B2 | Use of anthelmintic agents against Dirofilaria immitis | INTERVET INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170202816-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170196854-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INC. (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3177291-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | Intervet International B.V. (NL) | 2017-06-14 | — | — | EP | disclosed |
| EP-3166605-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | Intervet International B.V. (NL) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016005576-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INTERNATIONAL B.V. (NL) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016005577-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INTERNATIONAL B.V. (NL) | 2016-01-14 | — | — | WO | disclosed |
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| EP-2408742-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-09-03 | — | — | EP | disclosed |
| US-20040024024-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1385836-A2 | AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6683093-B2 | ENZYME INHIBITORS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-20040010019-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-01-15 | — | — | US | disclosed |
| WO-2004000811-A1 | ARYLSULFONYLHYDROXAMIC ACID AND AMIDE DERIVATIVES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003104223-A1 | PYRAZOLE-DERIVATIVES AS P38 KINASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003091247-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003045944-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030073718-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
| WO-2002092588-A2 | AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196854-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | MPO, DHODH, DHX35 | GBA1 847/4885ALDH1A1 1001/4885LMNA 4567/4885 |
| US-20180280367-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | MPO, DHODH, DHX35 | GBA1 847/4885ALDH1A1 1001/4885LMNA 4567/4885 |
| US-10010538-B2 | Use of anthelmintic agents against Dirofilaria immitis | MPO, DHODH, DHX35 | GBA1 847/4885ALDH1A1 1001/4885LMNA 4567/4885 |
| US-20030073718-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | MMP1, MMP7, MMP3 | GBA1 837/4885ALDH1A1 564/4885LMNA 1883/4885 |
| US-20170202816-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | MPO, DHODH, DHX35 | GBA1 847/4885ALDH1A1 1001/4885LMNA 4567/4885 |
| US-20040010019-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | MMP1, MMP3, MMP7 | GBA1 958/4885ALDH1A1 545/4885LMNA 1921/4885 |
| US-20040024024-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | MMP1, MMP3, MMP7 | GBA1 958/4885ALDH1A1 545/4885LMNA 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.